CAMO 2015_Final Program

CAMO 2015 ANNUAL SCIENTIFIC MEETING RÉUNION ANNUELLE SCIENTIFIQUE 2015 de l’ACOM FINAL PROGRAMME PROGRAMME FINAL Thursday, April 30, 2015 Jeudi le 30 avril 2015 The Chelsea Toronto, Ontario Co-­‐chair: Dr. Michael Vickers Co-­‐chair: Dr. Petr Kavan 2015 CAMO Annual Scientific Meeting Réunion annuelle scientifique de l’ACOM The Chelsea – Toronto, ON Thursday, April 30 / jeudi le 30 avril 2015 – Room: Mountbatten 07h00 – 17h00 CAMO Registration Desk Opens / Ouverture du bureau d’inscription de l’ACOM 07h00 – 08h15 Breakfast Symposium/Déjeuner Conférence 08h15 – 10h15 10h15 – 11h00 11h00 – 12h00 CAMO Oral Presentations/Présentations de résumés 12h10 – 13h30 12h10 – 13h30 13h45 – 14h00 Poster viewing and networking break/Présentations d’affiches et réseautage CAMO Morning Symposium (Keynote speaker) AGEISM VS TREATING THE FIT ELDERLY (HOW AGING AFFECTS PHARMACOKINETICS) Speaker: Dr. Michael Sawyer, Associate Professor, University of Alberta Objectives (45 minute presentation, followed by 10 minute Q&A) At the end of the session, participants will be able to: 1. List evidence that older patients experience more toxicity than younger patients. 2. Explain the changes in physiology in elderly patients that make them predisposed to chemotherapy toxicity. 3. Explain current and future methods to adjust chemotherapy in elderly to maintain efficacy and avoid toxicity. CAMO Annual General Meeting & Lunch/ Réunion d’affaires annuelle de l’ACOM & dîner (members only/membres seulement) (Room: Carlyle -­‐ 3rd Floor) Lunch for Delegates/Dîner des délégués (Room: Mountbatten) CAMO/RX&D Fellowship Presentations Best Resident Abstracts Dr. Kylea Potvin – Chair, Fellowship Committee Dr. Petr Kavan – Co-­‐chair, Annual Scientific Meeting Committee 14h00 – 16h55 14h00 – 14h05 CAMO Symposium "QUESTION FOR THE AGES: GERIATRIC ONCOLOGY" Introduction CAMO Symposium Dr. Kara Laing for (Dr. Michael Vickers) – Co-­‐chair, Annual Scientific Meeting Committee Dr. Petr Kavan – Co-­‐chair, Annual Scientific Meeting Committee 14h05 – 14h40 HOW COMPREHENSIVE DO WE NEED TO BE IN GERIATRIC ONCOLOGY Speaker: Dr. Camilla Wong, Geriatrician St. Michael’s Hospital, Assistant Professor, University of Toronto, Associate Scientist, Li Ka Shing Knowledge Institute Objectives (25 minute presentation, followed by 10 minute Q&A) At the end of the session, participants will be able to: 1. Discuss which geriatric domains should be assessed in the older oncology patient. 2. Explain how comprehensive assessment may alter discussions of prognosis. 3. Explain how comprehensive assessment may influence treatment decisions. 14h40 – 15h15 WHAT TOOLS TO USE TO ASSESS SUITABILITY OF OLDER ADULTS FOR CANCER TREATMENT? Speaker: Dr. Shabbir M.H. Alibhai, Staff Physician, Internal Medicine & Geriatrics, University Health Network & University of Toronto Objectives (25 minute presentation, followed by 10 minute Q&A) At the end of the session, participants will be able to: 1. Use validated online calculators to estimate remaining life expectancy. 2. Summarize the pros and cons of screening instruments for frailty in older cancer patients. 3. Calculate the risk of chemotherapy toxicity in older cancer patients using validated tools. 2015 CAMO Annual Scientific Meeting Réunion annuelle scientifique de l’ACOM The Chelsea – Toronto, ON Thursday, April 30 / jeudi le 30 avril 2015 – Room: Mountbatten (continued) 15h15 – 15h45 15h45 – 16h20 Poster viewing and networking break/Présentations d’affiches et réseautage CANCER SCREENING IN OLDER PATIENTS -­‐ WHEN IS IT TIME TO STOP? Speaker: Dr. Caroline Mariano, Royal Columbian Hospital Objectives (25 minute presentation, followed by 10 minute Q&A) At the end of the session, participants will be able to: 1. Discuss the evidence for screening elderly patients for breast and colorectal cancer. 2. Be able to use tools to estimate life expectancy. 3. Explain rationale for incorporation of life expectancy in screening decisions. 16h20 – 16h55 MAKING CLINICAL TRIALS RELEVANT FOR OLDER ADULTS WITH CANCER -­‐ CHOOSING SUITABLE ENDPOINTS Speaker: Dr. Tina Hsu, MD FRCPC, ABIM, The Ottawa Hospital Cancer Centre, University of Ottawa Objectives (25 minute presentation, followed by 10 minute Q&A) At the end of the session, participants will be able to: 1. Identify potential alternative endpoints available for use in clinical studies. 2. Identify what treatment outcomes are most important to older adults with cancer. 3. Describe potential methods to incorporate alternative endpoints into cancer trials. Thursday, April 30 / jeudi le 30 avril 2015 CAMO Awards Dinner* Ontario Heritage Trust, Ontario Heritage Center, 10 Adelaide Street East *CAMO members and one guest / Les membres de l’ACOM et un invité 18h30 – 19h00 Welcome reception/ Réception de bienvenue 19h00 – 22h00 CAMO Awards Dinner TOWARDS THE CURE OF METASTATIC COLORECTAL CANCER: A STORY OF A LONG JOURNEY Speaker: Dr. Jean Maroun, MD, FRCP(C), FRCP(London), Ottawa, ON Objectives (45 minute presentation, followed by 10 minute Q&A) At the end of the session, participants will be able to: 1. Provide information on evolving strategies in the treatment of metastatic colorectal cancer. 2. Provide information on new chemo-­‐therapies available in the treatment of metastatic colorectal cancer 3. Provide information on new biologic therapies and the emerging role of tumor markers in the management of metastatic colorectal cancer Upcoming CAMO meetings CAMO Pioneer Lecture Series Award Presentation CAMO Best Resident Abstract Award Presentation 2016 April 28 – Toronto, ON (The Chelsea) 2017 April 27 – Toronto, ON (The Chelsea) This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada. “This activity was approved by the Canadian Society of Internal Medicine”. La présente activité, approuvée par la Société canadienne de médecine interne, est une activité de formation collective agréée au titre de la section 1 conformément au programme de Maintien du certificat du Collège royal des médecins et chirurgiens du Canada. The Canadian Association of Medical Oncologists gratefully acknowledges the continued support of our scientific program by EDUCATIONAL GRANTS from: DIAMOND LEVEL Hoffmann-­‐La Roche Limited PLATINUM LEVEL Merck Canada Inc. Novartis Pharmaceuticals Canada Inc. SILVER LEVEL Amgen Boehringer Ingelheim (Canada) Ltd. Celgene Inc. BRONZE LEVEL Astellas Pharma Canada AstraZeneca Canada Bristol-­‐Myers Squibb Gilead Sciences Canada Inc. Ipsen Biopharmaceuticals Canada Inc. Pfizer Canada Inc.